Search
Amsacrine
go.drugbank.com/drugs/DB00276ApprovedInvestigationalWithdrawnIt produces consistent but acceptable myelosuppression and cardiotoxic effects. … It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.
Plerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigational[A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678] … These stem cells are then collected and used in autologous stem cell transplantation to replace blood-forming cells destroyed by chemotherapy.
Aluminum chloride
go.drugbank.com/drugs/DB11081ApprovedInvestigationalIn antiperspirant products, FDA approves the use of aluminum chloride as an active ingredient up to 15%, calculated on the hexahydrate form, in an aqueous solution nonaerosol dosage form [L2012].
Quavonlimab
go.drugbank.com/drugs/DB16422InvestigationalQuavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).
Iron
go.drugbank.com/drugs/DB01592ApprovedInvestigationalIron is used to build up the blood in anemia.
L-Acetylleucine
go.drugbank.com/drugs/DB16956ApprovedInvestigationalLevacetylleucine (L-acetylleucine) is a modified acetylated derivative of the amino acid leucine. The racemic (i.e. DL-) form has been available in France since 1957 for the treatment of vertigo. Observational studies in patients with Ni...
Etryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnαET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound. … In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's.
Tetrofosmin
go.drugbank.com/drugs/DB11180ApprovedTetrofosmin was developed to overcome the non-target uptake of radioligands by the generation of hetero-atomic compounds.
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487] … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.
MK-8666
go.drugbank.com/drugs/DB14937InvestigationalMK-8666 is under investigation in clinical trial NCT01971554 (Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)).